Comparative Pharmacology
Head-to-head clinical analysis: FOSPHENYTOIN SODIUM versus VIMPAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSPHENYTOIN SODIUM versus VIMPAT.
FOSPHENYTOIN SODIUM vs VIMPAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosphenytoin is a water-soluble prodrug of phenytoin. It is converted to phenytoin, which stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive firing of action potentials and reducing seizure propagation.
Selective enhancement of slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing.
Loading dose: 15-20 mg PE/kg IV at 100-150 mg PE/min; maintenance: 4-6 mg PE/kg/day IV divided every 8-12 hours.
Adults: 200 mg oral or IV as a loading dose, followed by 100 mg twice daily (200 mg/day) starting the day after loading. May increase by 50 mg twice daily every week up to 200 mg twice daily (400 mg/day).
None Documented
None Documented
The terminal elimination half-life of fosphenytoin is approximately 15 minutes (range 8-30 minutes) following IV administration; however, the half-life of the active metabolite phenytoin is 20-30 hours (dose-dependent) in adults, requiring careful monitoring for accumulation.
Terminal half-life: 13-16 hours (mean ~13 h at steady state); prolonged with renal impairment (CrCl <30 mL/min: ~22 h) and in patients with hepatic impairment (Child-Pugh B: ~17 h; Child-Pugh C: ~22 h).
Renal excretion of inactive metabolites (primarily fosphenytoin metabolites including phenytoin metabolites) accounts for approximately 80-90% of elimination; less than 5% excreted unchanged in urine; biliary/fecal excretion minimal.
Renal: ~95% (40% as parent drug, 39% as O-desmethyl metabolite, and ~15% as other minor metabolites); minimal biliary/fecal elimination (less than 1%).
Category D/X
Category C
Anticonvulsant
Anticonvulsant